PubRank

Andrew W Roberts

Author PubWeight™ 96.92‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006 10.19
2 ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013 8.89
3 Programmed anuclear cell death delimits platelet life span. Cell 2007 5.98
4 SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 2003 4.90
5 The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013 3.43
6 Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009 3.14
7 Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A 2006 3.06
8 SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. Immunity 2004 2.30
9 SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. J Clin Invest 2006 1.92
10 Granulocyte colony-stimulating factor and neutrophils--forgotten mediators of inflammatory disease. Nat Clin Pract Rheumatol 2006 1.85
11 In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc Natl Acad Sci U S A 2008 1.83
12 Suppressor screen in Mpl-/- mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling. Proc Natl Acad Sci U S A 2004 1.81
13 Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood 2012 1.81
14 Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 2009 1.74
15 Mcl-1 and Bcl-x(L) coordinately regulate megakaryocyte survival. Blood 2012 1.57
16 Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011 1.56
17 The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol 2009 1.39
18 The Rac2 guanosine triphosphatase regulates B lymphocyte antigen receptor responses and chemotaxis and is required for establishment of B-1a and marginal zone B lymphocytes. J Immunol 2002 1.35
19 A key role for G-CSF-induced neutrophil production and trafficking during inflammatory arthritis. Blood 2008 1.34
20 Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med 2011 1.27
21 Absence of suppressor of cytokine signalling 3 reduces self-renewal and promotes differentiation in murine embryonic stem cells. Stem Cells 2005 1.22
22 The threshold of gp130-dependent STAT3 signaling is critical for normal regulation of hematopoiesis. Blood 2005 1.22
23 Fas-mediated neutrophil apoptosis is accelerated by Bid, Bak, and Bax and inhibited by Bcl-2 and Mcl-1. Proc Natl Acad Sci U S A 2011 1.18
24 Critical role for granulocyte colony-stimulating factor in inflammatory arthritis. Proc Natl Acad Sci U S A 2004 1.18
25 The SOCS box of suppressor of cytokine signaling-3 contributes to the control of G-CSF responsiveness in vivo. Blood 2007 1.13
26 Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. Br J Haematol 2010 1.12
27 Thrombocytopenia and kidney disease in mice with a mutation in the C1galt1 gene. Proc Natl Acad Sci U S A 2006 1.09
28 Regulation of interleukin-1beta by interferon-gamma is species specific, limited by suppressor of cytokine signalling 1 and influences interleukin-17 production. EMBO Rep 2010 1.05
29 Rac2-deficient mice display perturbed T-cell distribution and chemotaxis, but only minor abnormalities in T(H)1 responses. Immunol Cell Biol 2002 1.04
30 Genetic reduction of embryonic leukemia-inhibitory factor production rescues placentation in SOCS3-null embryos but does not prevent inflammatory disease. Proc Natl Acad Sci U S A 2005 1.04
31 Structural basis for apoptosis inhibition by Epstein-Barr virus BHRF1. PLoS Pathog 2010 1.02
32 Pathologic consequences of STAT3 hyperactivation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis. Blood 2006 1.02
33 Proapoptotic Bak and Bax guard against fatal systemic and organ-specific autoimmune disease. Proc Natl Acad Sci U S A 2013 0.98
34 A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. Leuk Lymphoma 2014 0.96
35 Neutrophils require SHP1 to regulate IL-1β production and prevent inflammatory skin disease. J Immunol 2010 0.95
36 IL-6 promotes acute and chronic inflammatory disease in the absence of SOCS3. Immunol Cell Biol 2011 0.93
37 Hematopoietic abnormalities in mice deficient in gp130-mediated STAT signaling. Exp Hematol 2002 0.92
38 Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies. Pathology 2011 0.91
39 Socs3 maintains the specificity of biological responses to cytokine signals during granulocyte and macrophage differentiation. Exp Hematol 2008 0.91
40 SOCS3 regulates graft-versus-host disease. Blood 2010 0.89
41 Regulation of multiple cytokine signalling pathways by SOCS3 is independent of SOCS2. Growth Factors 2009 0.89
42 The effect of community pharmacy-based interventions on patient health outcomes: a systematic review. Med Care Res Rev 2012 0.85
43 Deficiency of 5-hydroxyisourate hydrolase causes hepatomegaly and hepatocellular carcinoma in mice. Proc Natl Acad Sci U S A 2010 0.84
44 Mechanism of crosstalk inhibition of IL-6 signaling in response to LPS and TNFalpha. Growth Factors 2007 0.84
45 Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034). Blood 2009 0.83
46 More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders. Blood 2006 0.82
47 Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 2003 0.82
48 Perturbed thymopoiesis in vitro in the absence of suppressor of cytokine signalling 1 and 3. Mol Immunol 2008 0.81
49 Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy. Br J Haematol 2002 0.81
50 Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma. Clin Cancer Res 2009 0.79
51 Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood. Pathology 2006 0.79
52 Racial disparities across provider specialties in opioid prescriptions dispensed to medicaid beneficiaries with chronic noncancer pain. Pain Med 2014 0.78
53 BH3 mimetic therapy: an emerging and promising approach to treating chronic lymphocytic leukemia. Leuk Lymphoma 2013 0.78
54 North Carolina Medicaid recipient management lock-in program: the pharmacist's perspective. J Manag Care Spec Pharm 2014 0.77
55 Bortezomib: putting mantle cell lymphoma on death row. Leuk Lymphoma 2008 0.77
56 Towards a four-dimensional view of neutrophils. Methods Mol Biol 2012 0.76
57 BCL2 inhibition in double hit lymphoma. Leuk Lymphoma 2015 0.76
58 Validating the allogeneic stem cell transplantation disease risk index: sample size, follow-up, and local data are important. Transplantation 2015 0.75
59 Donald Metcalf (1929-2014). Cell 2015 0.75
60 New Agents to Treat Chronic Lymphocytic Leukemia. N Engl J Med 2016 0.75
61 BH3-mimetics--the solution to chemoresistance? Leuk Lymphoma 2009 0.75
62 Low adhesion receptor levels on circulating platelets in patients with lymphoproliferative diseases before receiving Navitoclax (ABT-263). Blood 2013 0.75